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Abstract
Human papillomaviruses (HPV) are a large family of viruses which contain a circular, double-stranded DNA genome of
approximately 8000 base pairs. The viral DNA is chromatinized by the recruitment of cellular histones which are subject to host
cell–mediated post-translational epigenetic modification recognized as an important mechanism of virus transcription regulation.
The HPV life cycle is dependent on the terminal differentiation of the target cell within epithelia—the keratinocyte. The virus life
cycle begins in the undifferentiated basal compartment of epithelia where the viral chromatin is maintained in an epigenetically
repressed state, stabilized by distal chromatin interactions between the viral enhancer and early gene region. Migration of the
infected keratinocyte towards the surface of the epithelium induces cellular differentiation which disrupts chromatin looping and
stimulates epigenetic remodelling of the viral chromatin. These epigenetic changes result in enhanced virus transcription and
activation of the virus late promoter facilitating transcription of the viral capsid proteins. In this review article, we discuss the
complexity of virus- and host-cell-mediated epigenetic regulation of virus transcription with a specific focus on differentiation-
dependent remodelling of viral chromatin during the HPV life cycle.
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Introduction
At the time of writing, the Papillomaviridae (PV) family of
viruses is composed of over 450 distinct types of human pap-
illomavirus (HPV) and over 200 animal papillomaviruses
(http://pave.niaid.nih.gov). Each PV type is defined by a >
2% difference in sequence from any other know type. PV
types are arranged into distinct genera that share > 60%
identity in the L1 open reading frame (ORF). HPV types are
phylogenetically arranged in five genera; alpha, beta, gamma,
mu and nu [1]. All known HPV types occupy a tightly defined
niche; they exclusively replicate in keratinocytes within
squamous epithelia of either the cutaneous or mucosal
surfaces of the human body. Infection with the vast majority
of HPV types results in benign disease that is often sub-
clinical, but can develop into the growth of papillomas or
warts at the epithelial surface. A subset of HPV types
(HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 66)
are the causative agent of cancers of the anogenital and
oropharyngeal tracts and defined as group I carcinogens by
the World Health Organization [2]. Due to their association
with cancer development, these so called high-risk HPV types
have been most widely studied and will therefore be the focus
of this review.
HPV genome structure
The genome of all HPV types has a similar arrangement char-
acterized by an approximately 8000 base pair circular
doubled-stranded DNA genome encased in a non-enveloped
icosahedral capsid of about 55 nm in diameter [1]. The viral
genome contains 7–9 open reading frames (ORF) divided into
early (E1, E2, E4, E5, E6, E7 and E8, although E5 and E8
ORF are not present in the genomes of all HPV types) and late
(L1 and L2) genes (Fig. 1a). The core proteins, E1 and E2,
have key roles in viral DNA replication and amplification, and
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regulating viral transcription, and the L1 and L2 proteins form
the capsid, as well as L2 having a role in delivery of the viral
genome to the nucleus upon infection and viral genome
encapsidation during capsid assembly. Accessory proteins in-
clude E4, E5, E6 and E7 and these proteins facilitate the dif-
ferent stages of the vegetative virus life cycle primarily by
forming virus-host interactions to alter the environment of
the keratinocyte to support viral replication and enable eva-
sion of host anti-viral defences. For the high-risk HPV types,
the key players in oncogenesis are the oncoproteins E5, E6
and E7. A non-coding region referred to as the upstream reg-
ulatory region (URR; also known as the long control region
(LCR)) is situated upstream of the early region (Fig. 1a). This
region contains binding sites for a plethora of transcription
and regulatory factors that either activate or repress the early
(E) and late (L) promoters (PE: P97 - HPV16, P105 - HPV18;
PL: P670 - HPV16; P811 - HPV18), the origin of replication to
which the E1 protein binds, as well as multiple binding sites
for the viral E2 protein. Relevant to this review was a study in
the 1970s that showed that the HPV genome does not exist in
a naked state in an productive lesion but as a nucleoprotein
complex containing cellular histones [3](Fig. 1b).
HPV transcription
Several promoters within the HPV genome have been identi-
fied, but for the purposes of this review, we will mention here
only the early promoter (PE) that is active in undifferentiated
basal keratinocytes, the late promoter (PL) that lies within the
E7 ORF and becomes active in differentiated keratinocytes,
and the PE8 promoter present within the E1 ORF which con-
trols the expression of an E8^E2 protein that regulates viral
transcription and viral DNA replication. Alternative RNA
splicing leads to the production of multicistronic viral messen-
ger RNAs transcribed from one strand of the genome. Early
transcripts initiate from PE and terminate at the early
polyadenylation (PolyA) site (PAE) situated at the end of the
E5 ORF (Fig. 1a). Transcripts from the differentiation-
regulated PL also utilize the early PolyA site but those that
encode the structural proteins terminate at the late PolyAmotif
(PAL) present in the URR. The PE8 promoter is active through-
out the infectious cycle and unlike PE and PL, constitutive
activation of PE8 is not controlled by the viral enhancer ele-
ments situated within the URR [4].
The programme of HPV transcription is intimately linked
to the physiology of the keratinocyte and all stages of RNA
metabolism are regulated during the virus life cycle, including
promoter usage, polyadenylation, splice site usage, mRNA
stability and translation (reviewed in [5]). The overall effect
of this complex, differentiation-specific programme ensures
that low levels of those early proteins necessary for initial
amplification and establishment of the viral genome are
expressed in basal cells. As differentiation occurs and the life
cycle switches to the vegetative cycle, the expression levels of
Fig. 1 HPV genome organization. a The circular, double-stranded HPV
genome is about 8000 base pairs and divided into three regions: the early,
late and non-coding upstream regulatory region (URR). The early region
contains open-reading frames (ORF), some overlapping of E1, E2, E4,
E5, E6, E7 and E8. The late region contains L1 and L2 ORF—the capsid
proteins. Viral transcription is controlled by the HPV E2 protein and host
factors binding sequences within the URR. The main promoters are the
early PE, the late PL and the E8 promoter PE8, and viral transcripts
terminate at the early pAE or late pAL poly-adenylation sites. The URR
also contains the origin of replication. b In a study in the late 1970s [3],
electron microscopy of metal-shadowed HPV genomes isolated from
plantar warts showed naked HPV DNA molecules (left) and
nucleoprotein-DNA complexes (right) revealing an intricate ‘beads on a
string’ conformation of nucleosomes. Reproduced with permission from
the American Society for Microbiology
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these proteins rise along with E4, E5, E6 and E7 to alter the
keratinocyte milieu to enable viral DNA amplification and
restrict expression of the structural proteins necessary for vi-
rion assembly in the upper most differentiated cells. One key
aspect of this programme is that it avoids high expression
levels of the viral proteins in basal keratinocytes and thereby
avoids activation of host immune pathways. Integral to this
control process of HPV transcription is epigenetic modifica-
tion of the viral chromatin.
HPV life cycle
HPVs infect basal keratinocytes, the proliferative compart-
ment of squamous epithelia, through wounds and micro-
abrasions in the epithelium (Fig. 2). Keratinocyte infection is
a lengthy multi-step cascade of host factor binding and
protease-induced capsid conformational changes initiated fol-
lowing virion binding to heparin sulphate proteoglycans on
the basal lamina. Upon mitosis of the infected keratinocyte,
the incoming viral genome in complex with the minor capsid
protein L2 is bound to the condensed chromatin. Following an
initial phase of viral DNA amplification, the episomal genome
is established at a copy number of approximately 50 to 100
copies per cell. The early proteins E1 and E2 along with host
replication factors including DNA polymeraseα/primase, rep-
lication protein A and topoisomerase I facilitate viral DNA
replication; E1 functioning as an ATP-dependent DNA
helicase to unwind the double-stranded DNA and E2 acting
as a sequence-specific DNA binding protein to load E1
helicase onto the viral origin of replication in the URR
(Fig. 3a).
The maintenance phase of HPV DNA replication occurs in
synchrony with the host DNA which ensures equal
partitioning of the viral episomes to daughter cells. E2 plays
a central role in this process by tethering the viral genomes to
host chromatin to ensure efficient inheritance of the viral
DNA. The viral genomes are tethered to different regions of
mitotic chromosomes and this involves interaction of E2 with
different host factors, including the epigenetic reader
bromodomain protein Brd4, the DNA helicase chromosome
loss-related 1 (ChlR1) and topoisomerase binding protein 1
(TopBP1) (reviewed in [6]). E2-mediated tethering via Brd4
association also appears to be important for positioning viral
genomes to host genomic fragile sites that contain large and
actively transcribed genes in epigenetically active chromatin
[7].
E2 protein function is also central to virus transcription
control. There are four conserved palindromic E2 binding
sites within the URR of high-risk alpha-HPVs with the con-
sensus sequence ACCG(N)4CGGT that each binds an E2 di-
mer [8] (Fig. 3a). Binding of E2 to these sites can either acti-
vate or, more commonly, repress transcription depending on
the sequence context of the occupied E2 sites within the URR.
The mechanism of E2-dependent transcriptional repression is
both through steric hindrance of transcriptional activators such
as TATA binding protein (TBP) and specificity protein 1 (SP1)
Fig. 2 HPV life cycle organization. The HPV life cycle is dependent on
the terminal differentiation of the keratinocyte. The virus life cycle begins
by the viral particle (red pentagon) gaining access to the basal lamina and
then infecting the mitotically active basal keratinocyte. The viral genome
(black circle) is established as an extra-chromosomal replicon and
maintained in basal cells until the cell differentiates and HPV early
protein expression increases. Differentiating cells are pushed back into
cell cycle and the viral genome amplifies to high copy number. Finally,
the cell completes differentiation, expresses the viral late structural
proteins L1 and L2 enabling virion assembly and egress. A viral
regulator E8^E2 regulates viral transcription and replication and can
also inhibit its own promoter PE8 suggesting that levels of the regulator
may be finely tuned during the life cycle
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to proximal promoter elements [9–13] or by facilitating re-
cruitment of cellular factors that mediate epigenetic regulation
of the viral chromatin [14–16].
The E8^E2 protein is encoded by a transcript that origi-
nates from the PE8 promoter situated within the E1 ORF of
many but not all animal and human papillomavirus types. The
E8^E2 product is formed from an alternative exon within the
E1 ORF (E8) spliced into the 3′ exon of the E2 gene such that
E8^E2 protein contains a novel N-terminal domain fused to
the DNA-binding domain of E2 [17]. As such, E8^E2 is un-
able to bind to the E1 helicase and many of the cellular tran-
scriptional regulators bound by the N-terminal domain of full
Fig. 3 Epigenetic regulation of the HPV transcription during the virus life
cycle. Binding of nucleosomes to the HPV URR (contains the enhancer,
origin of replication (Ori) and proximal promoter PE), epigenetic
modifications (DNA methylation (CpG Me), histone methylation (Me)
and histone acetylation (Ac)) and some of the major host epigenetic
modifiers involved are shown in undifferentiated (a) and differentiated
keratinocytes (b). Details are given in the text. Strongly bound
nucleosomes are shown in dark blue, weakly bound in faint blue, and
nucleosomes that are lost or repositioned upon differentiation are shown
in faint blue and with dotted lines. Questionmarks (?) indicate uncertainty
of the epigenetic modification occurring in differentiated cells. Plus and
minus signs indicate stimulation or repression of viral transcription. Host
factors known to bind the URR that are relevant to this review are shown
only, alongside E1 and E2 binding
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length E2 but retain the ability to homo- and hetero-dimerize
with full length E2 and bind to E2 DNA binding sites in the
viral URR [18]. E8^E2 is therefore a strong repressor of HPV
replication by excluding E1 from the origin of replication, and
of E2-dependent transcription activation by preventing the
recruitment of E2-associated transcriptional activators to the
URR. Although PE8 is constitutively active and independent
of enhancer elements with the HPV URR, E8^E2 is able to
strongly inhibit its own promoter but E2 weakly activates it.
Such fine tuning of E8^E2 expression requires E2/E8^E2
binding within the URR and is thought to represent a mecha-
nism whereby HPV controls viral copy number [4].
Once the infected cell moves from the basal lamina, the
normal entry into differentiation is delayed and early gene
expression increases with stimulation of PE and PL activities.
E5, E6 and E7 protein functions synergize to promote cell
cycle re-entry and proliferation, and survival of post-mitotic
keratinocytes to orchestrate viral DNA replication competent
cells. They do so by targeting the components of key growth
control pathways including p53 and retinoblastoma, as well as
pathways that enable the virally infected cells to avoid im-
mune detection [19]. The virus also deregulates epigenetic
control of host gene expression contributing to the prolifera-
tive state and survival of the infected cell [20]. To avoid com-
peting with host DNA replication during S phase, viral DNA
amplification occurs in the G2 phase of the cell cycle, and by
activating the ATM DNA damage repair pathways, HPV uti-
lizes the repair factories that form to replicate its genome dur-
ing this phase [21]. Once viral DNA amplification is complet-
ed, E2 binds to sites within the URR to repress the expression
of early proteins and cell cycle activity ceases, enabling
keratinocyte differentiation and the expression of the late
structural proteins L1 and L2. This late productive stage en-
compasses viral genome encapsidation, maturation of proge-
ny virus and the sloughing off of superficial cells packed with
infectious new progeny from the epithelial surface. The veg-
etative phase is accompanied by expression of large quantities
of E4, a viral protein of ill-defined function but one that con-




DNA in the nucleus of eukaryotic cells is wrapped around
octameric complexes of proteins called histones, composed
of dimers of H2A, H2B, H3 and H4. Each histone core is
wrapped by ~ 147 base pairs of DNA [23] to form nucleo-
somes that create a classical ‘beads-on-a-string’ conformation
known as chromatin. Chromatin structure is central to the
control of gene transcription as the arrangement of
nucleosomes on regulatory units controls accessibility to tran-
scription factors. Histones can be covalently modified on the
N-terminal tails that protrude from the core histone complexes
by a series of enzymes known as writers including DNA
methyltransferases (DNMTs), histone lysine methyltransfer-
ases, protein arginine methyltransferases and histone acetyl-
transferases (HATs). Such modifications include mono-
(Me1), di- (Me2) and tri- (Me3) methylation, hydroxy-
methylation and acetylation (Ac) which are added to a pleth-
ora of arginine (R) and lysine (K) residues within the protrud-
ing N-terminal tails of histones. In altering the affinity of his-
tones for DNA, specific covalent modification of histones can
differentially recruit or disrupt the binding of factors termed
readers that further regulate chromatin structure and function,
such as remodelling enzymes that drive repositioning of his-
tones (for review see [24]).
Through epigenetic modification, chromatin exists in dif-
ferent physical states to regulate transcription. Tightly packed,
closed chromatin known as heterochromatin is transcription-
ally repressed, whereas open chromatin known as euchroma-
tin is permissive for gene transcription as it contains much less
densely packed and dynamically associated histones allowing
transcription factors to access regulatory elements and drive
transcription. These general forms of chromatin are dictated
by post-translational modification (PTM) of histones or by
direct, covalent methylation of DNA. Heterochromatin is gen-
erally characterized by enrichment of repressive epigenetic
marks such as H2K4Me2/3, H3K9Me1, H3K27Me2/3 and
H4K20Me3. Acetylation of histones decreases their affinity
to DNA and as such open euchromatin is enriched in epige-
netic marks including H3K4Ac and H3K27Ac [25]. The di-
versity of histone PTMs that regulate the epigenome creates a
gradient of chromatin structure ranging from heterochromatin
to repressed but permissive chromatin that can be rapidly ac-
tivated to constitutively active chromatin. Reversible changes
to chromatin that influence gene expression were first
hypothesised in 1942 [26]. Evolution of this initial hypothesis
over many decades of research has now defined epigenetics as
heritable changes occurring in the genome that regulate gene
expression patterns without affecting the underlying DNA se-
quence. Epigenetic regulation of gene expression is crucial in
cellular programming during development and in the regula-
tion of cellular processes and response to environmental stim-
uli without altering the underlying genetic code.
DNA methylation
DNA can be directly methylated on the 5′ position of the
cytosine pyrimidine ring creating 5-methylcytosine (5mC).
This covalent modification most often occurs on cytosines
preceding a guanine (CpG), and is catalysed by DNA meth-
yltransferases (DNMTs) which catalyse either maintenance or
de novo DNA methylation (reviewed by [27]). While CpG
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methylation occurs globally across the genome, there are large
clusters of these sites, known as CpG islands [28]. CpG
islands are important in regulating chromatin structure and
gene expression control. Up to 60% of gene promoters contain
CpG islands in which methylation blocks transcription initia-
tion. However, methylation within gene bodies can also en-
hance transcription and alter gene splicing [29]. DNA meth-
ylation regulates gene silencing via a number of mechanisms.
It can mediate the direct inhibition of essential protein-DNA
interactions and reduce chromatin accessibility [30]. CpG
methylation is also known to recruit methyl-CpG binding pro-
teins (MeCPs), resulting in further alteration of chromatin
structure [31]. Cytosine methylation is mediated by three
key members of the DNMT family which possess methyl-
transferase activity. The activity of DNMT1 is preferential
for hemi-methylated DNA and is often referred to as a main-
tenance methyltransferase while the DNMT3 family
(DNMT3A, DNMT3B) can also catalyse de novo DNA
methylation.
Epigenetic regulation of HPV transcription
HPV chromatin structure
The association of histone complexes with encapsidated HPV
DNAwas first described by Favre and colleagues in 1977 [3].
Electrophoresis of highly purified HPV virions revealed asso-
ciation with proteins of similar molecular mass to the canon-
ical histone complex, H2A, H2B, H3 and H4, and it was
estimated that these histone-like proteins constituted 87% of
the total DNA-associated protein. Nucleated HPV DNA was
analysed by electron microscopy which revealed an intricate
‘beads on a string’ conformation with each nucleosome mea-
suring 12 nm in diameter corresponding to canonical nucleo-
somal formation. Up to 32 nucleosome complexes were ob-
served on the complete HPV genome and interestingly, the
interconnecting DNA was of variable length indicating
sequence- or regulatory element–dependent positioning of nu-
cleosomes (Fig. 1b). The precise arrangement of nucleosomes
on the viral enhancer and promoter elements is likely to be
fundamental to virus transcription regulation. Nucleosome
mapping demonstrates that at least two nucleosomes are lo-
cated within the URR in HPV16 and 18, one overlapping with
the viral enhancer and a second overlapping with the E1 bind-
ing site within the replication origin and SP1 binding site in
the early promoter [32] (Fig. 3a). The nucleosome positioning
at the early promoter functions to repress virus transcription
by excluding SP1 recruitment [32]. However, the replication
origin and early promoter have been shown to have weaker
affinity for histones than other areas of the viral genome [33],
suggesting that this nucleosome is easily displaced to activate
transcription and/or replication. Increased SP1 concentration
can displace this nucleosome in vitro [32]. The E1 and E2
proteins have also been shown to induce a change in nucleo-
somal positioning [33, 34] suggesting that nucleosome ar-
rangement is dictated by DNA sequence as well as the binding
of host and viral factors. Further three nucleosomes are posi-
tioned at the late promoter within the E6 ORF and 5′ end of the
E7 ORF [32, 35] (Fig. 3a). Interestingly, significant remodel-
ling of chromatin structure with the E7 ORF occurs upon
keratinocyte differentiation to increase accessibility and acti-
vation of the late promoter [35] (Fig. 3b).
Histone acetylation
HPV has been shown to interact with several HATand HDAC
family members to regulate viral transcription. CREB-binding
protein (CBP) and its paralogue p300 are transcriptional
coactivators that bind DNA-bound transcriptional regulators
and acetylated histones. Once bound to a promoter, CBP/p300
recruit the basal transcription machinery to activate transcrip-
tion. CBP/p300 also have intrinsic HAT activity and can acet-
ylate histones [36], thereby causing relaxation of DNA at
transcriptional promoters, and basal transcription factors to
further activate transcription [37]. Numerous studies have
demonstrated a role for p300 in maintaining the high expres-
sion of E6/E7 in cervical cancer cells. The E2, E6 and E7
proteins from various HPV types have all been shown to bind
to p300 [38–41]. HPV E2 and p300 cooperate to activate the
HPV early promoter cloned into transcriptional reporter con-
structs [42] and the interaction between E7 and p300 may be
an important feedback loop as E7 abrogates CBP/p300-
mediated E2 transactivation [41]. CBP/p300 can also bind to
the HPV18 URR in the absence of E2 as recruitment has been
demonstrated in E2-negative cervical cancer cells [43]. CBP/
p300-dependent E6/E7 transcription activation is associated
with acetylation of H3 at the HPV URR providing evidence
that CBP/p300 activates HPV transcription by altering the
epigenetic status of the viral enhancer/promoter [44].
Increased histone acetylation by CBP/p300 results in en-
hanced recruitment of the SWI/SNF chromatin remodelling
complex catalytic subunit, the Brahma-related gene-1
(Brg1), to the URR which is required for efficient RNA poly-
merase II recruitment [45]. Interestingly, chemical inhibition
of p300 HAT activity inhibits E6/E7 mRNA expression and
induces apoptosis cervical cancer cells [46], suggesting that
CBP/p300 inhibition may be an effective anti-HPV strategy.
While these studies demonstrate a role for CBP/p300 in the
sustained E6/E7 expression in HPV-driven cancer, the func-
tion of HAT activity in the productive virus life cycle is not
understood although increased histone acetylation has been
detected at the URR and late promoter following host cell
differentiation.
In the context of an HPV infection, E2 functions to repress
E6/E7 transcript production. In an siRNA screen designed to
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identify cellular factors that contribute to E2-mediated repres-
sion of the HPV18 URR, EP400, a component of the
NuA4/TIP60 histone acetylase complex was identified [15].
Acetylation of histones in the HPV URR by TIP60 results in
the recruitment of bromodomain containing protein Brd4 [47].
Brd4 is a strong corepressor of E2-dependent HPV transcrip-
tion [15, 16]. Therefore, rather than functioning as a coactiva-
tor of transcription as is the canonical function of TIP60, re-
cruitment of TIP60 to the URR results in Brd4 recruitment and
strong transcriptional repression.
Sirtuins (SIRT1-SIRT7) are a protein family of class III
HDACs that function in DNA damage repair and apoptosis.
The stable maintenance of HPV16 and HPV31 episomes
within human foreskin keratinocytes results E6/E7-
dependent elevation of SIRT1 expression. This increase is
maintained within differentiated keratinocytes [48]. SIRT1
promotes HPV episome replication in undifferentiated
keratinocytes and genome amplification upon differentiation
and is important for late transcription production in differen-
tiated cultures [48, 49]. In undifferentiated cells, SIRT1 binds
to the HPV31 URR and deacetylates histone 1 at Lys26
(H1K26Ac) and histone 4 at Lys16 (H4K16Ac), enabling re-
pression of late gene transcription. SIRT1 also stimulates the
recruitment of Werner helicase (WRN) to enhance E1-E2-
dependent replication fidelity [50]. Following differentiation,
SIRT1 binding to HPV episomes is significantly reduced
resulting in the hyperacetylation of histone-1 (Lys26) and en-
hanced late gene expression [48]. Interestingly, SIRT1 knock-
out results in reduced E2 protein acetylation suggesting that
E2 is a direct target for SIRT1 [49]. Further epigenetic repres-
sion of the viral URR is mediated by E8^E2-mediated recruit-
ment of the HDAC3-containing NCoR/SMRT transcriptional
repressor complex [51].
Histone methylation
The viral episome in undifferentiated keratinocytes exists in a
repressed chromatin state in part by the recruitment of
polycomb repressor complexes 1 and 2 (PRC1/2) which ca-
talyse deposition of repressive H3K27Me3 and H3K119Ub
[52]. While this is likely to be important for the productive
virus life cycle, integration of viral DNA and upregulation of
viral oncogene E6/E7 expression have been shown to corre-
late with enrichment of open chromatin at the HPV16 LCR
and early promoter, mediated by chromatin remodelling en-
zymes Brg1 and INI1 (hSNF5/SmarcB1) [53]. This disease-
associated alteration of the epigenetic status of HPV chroma-
tin increases the accessibility of positive transcriptional regu-
lators including c-Jun and histone lysine methyltransferases,
including SETD1A and MIL1, which catalyse deposition of
transcriptionally active histone marks, including H3K4me3
creating a favourable landscape for RNA polymerase II re-
cruitment which drives HPV16 oncogene transcription from
the early promoter [53]. Whether this is important in the pro-
ductive virus life cycle has yet to be determined.
The histone methyltransferase SETD2 is a writer of
trimethylation of histone 3 lysine 36 (H3K36me3), a mark
of active transcription. High-risk E7 mediates the post-
transcriptional stabilization of SETD2 resulting in increased
levels in HPV31 and HPV16 containing human foreskin
keratinocytes. SETD2-dependent H3K36me3 deposition is
apparent throughout the viral genome and enriched at the 3′
end of the early gene region in both undifferentiated and dif-
ferentiated keratinocytes and is essential for both maintenance
and productive viral replication [54]. Interestingly, the DNA
damage kinase enzyme ataxia-telangiectasia mutated (ATM)
is required for maintenance of H3K36Me3 on viral chromatin
presumably through inhibition of the demethylases KDM2A
and/or KDM4A suggesting that ATM not only facilitates re-
cruitment of DNA damage repair factors to the viral genome
but also influences epigenetic status [54]. Conversely, HPV
E7 has been shown to enhance cellular expression of the
H3K27Me3 demethylase KDM6A, resulting in de-
repression of host genes [55] but the consequences of
KDM6A upregulation on the epigenetic status of the viral
genome have not been studied.
CpG DNA methylation
The first evidence of epigenetic modification of HPV DNA
was in the form of covalent methylation of CpG dinucleotides
on HPV1 DNA [56, 57]. It was initially demonstrated that
CpG methylation of integrated HPV18 DNA in tumourigenic
and non-tumourigenic cell lines has an inverse correlation
with virus transcript levels. In addition, treatment of HeLa
cells with the DNAmethylation inhibitor 5-azacytidine result-
ed in reduced HPV mRNA expression [58]. Purified HPV18
DNA can be CpG methylated in vitro resulting in attenuation
of activity of transfected HPV transcription reporters [59].
Differentially methylated CpG dinucleotides are present with-
in consensus E2 binding sites in the URR and CpG methyla-
tion at these sites inhibits E2 binding, alleviating E2-mediated
repression of E6/E7 oncogenes [60]. CpG methylation chang-
es that are initiated by cellular differentiation may influence
E2-dependent virus transcription during the HPV life cycle
although this is not understood. Studies in HPV16-episome
containing W12 cells derived from a naturally occurring low-
grade cervical lesion [61] demonstrated that the viral LCR is
enriched in methylated CpG dinucleotides in poorly differen-
tiated cells and become hypomethylated upon cellular differ-
entiation [62]. Although it has also been noted that episomal
HPV DNA in premalignant biopsy material is unmethylated
suggesting that de novo methylation may occur after integra-
tion of HPVDNA into the host to attenuate production of viral
transcripts, which could result in viral latency [59].
Transcriptionally silent HPV integrants can be found in the
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healthy cervices of older women suggesting that such a mech-
anism of HPV latency may be at play [63].
Modulation of CpGmethylation of HPVDNA is important
during carcinogenesis. Several studies have demonstrated a
correlation between increased CpG methylation within the
late gene region of integrated viral sequences and disease pro-
gression [64–67]. High-grade cervical intraepithelial neopla-
sia (CIN2+) cases show significantly higher methylation com-
pared with HPV DNA clearance controls and this was found
to be largely associated with the L1 and L2 ORFs [65].
Interestingly, a correlation between increased methylation sta-
tus of E2 binding sites in the URR in the presence of an intact
E2 ORF and disease severity has been reported in oropharyn-
geal squamous cell carcinomas (OPSCC) [68]. Since the DNA
binding affinity of E2 is reduced by CpG methylation, this is
likely to explain why CpG methylation of the HPV URR
correlates with increased E6/E7 expression compared with
tumours with undetectable methylation [60, 68], and that
high-grade OPSCC frequently have high E2 expression com-
bined with high E6/E7 expression [69].
Differentiation-dependent regulation
of the HPV epigenome
Stimulation of keratinocyte differentiation results in an in-
crease in transcripts that originate from the early protomer
and the appearance of transcripts that are initiated from within
the E6/E7 ORFs around the late promoter [35, 70, 71].
Sequences within the URR and E6/E7 gene regions are re-
quired for late promoter activation [72] and it was proposed
that differentiation-dependent regulation of HPV transcription
was initiated by changes to chromatin structure in these re-
gions enhancing accessibility to host transcriptional regula-
tors. DNase I footprinting experiments identified a region
within the E7 ORF that was depleted of histone proteins fol-
lowing differentiation of HPV31 episome harbouring
keratinocytes [35]. Differentiation-induced enhancement of
chromatin accessibility was shown to be due to alterations in
epigenetic status of the viral chromatin including dramatic
enhancement of H3 and H4 acetylation and H3K4Me2 at both
the early and late promoters [73]. These changes in chromatin
structure are co-incident with enhanced binding of cellular
transcriptional activators such as C/EBP-β and c-Jun to the
keratinocyte specific enhancer within the URR [73].
YY1 is a strong repressor of the HPV keratinocyte specific
enhancer [74, 75] and functions as a transcriptional repressor
by facilitating the recruitment of the Polycomb group (PcG) of
proteins to chromatin [76–78]. PcG proteins are epigenetic
writers that assemble into multimeric complexes including
the Polycomb repressive complexes 1 and 2 (PRC1, PRC2).
PRC1 functions as a ubiquitin ligase which specifically
ubiquitinylates H2A lysine 119 (H2AK119Ub) [79]. PRC2
contains the methyltransferase Enhancer of Zeste homologue
2 (Ezh2) which catalyses transcriptionally repressive
H3K27Me3 deposition [80]. PRC1 and PRC2 are enriched
on HPV18 URR in undifferentiated keratinocytes coincident
with the enrichment of H3K27Me3 and H2K199Ub, and re-
pression of virus transcription [52]. Studies have shown that
expression of E6 and E7 from HPV types 16, 18 and 38
induces increased Ezh2 protein levels, which was shown to
be required for the proliferation of HPV-positive tumour cells
although a concomitant increase in H3K27Me3 levels was not
observed [81–83]. This apparent disconnect is thought to be
due to enhanced phosphorylation of Ezh2 at serine 21 induced
by E6/E7 expression [82], which inhibits the enzymatic activ-
ity of Ezh2 [84]. It would be interesting to determine whether
this represents a positive feedback mechanism of HPV tran-
scription activation resulting from differentiation-induced en-
hancement of E6/E7 expression.
Chromatin binding architectural proteins such as the zinc-
finger CCCTC-binding factor CTCF are fundamental in the
three-dimensional organization of chromatin. CTCF is a ubiq-
uitously expressed DNA-binding protein that binds tens of
thousands of sites in the human genome [85] and functions
as an epigenetic boundary insulator, transcriptional activator
and repressor [86]. By facilitating the formation of chromatin
loops at sites that are also enriched in cohesin [87], CTCF is
important in the maintenance of long-range chromatin inter-
actions [88]. Interestingly, the majority of genomic chromatin
loops are stabilized by CTCF bound to inverted cognate sites
[89] and inversion of specific CTCF sites has profound effects
on chromatin loop formation [90]. The specificity of CTCF
binding site orientation has been central to the hypothesis that
chromatin loops are formed by extrusion of the DNA through
cohesin rings that are blocked by CTCF ‘anchors’ at specific
genomic loci. Whether there is a specific motor complex that
drives chromatin loop extrusion is yet to be decided, but the-
oretical modelling suggests that loop extrusion may occur via
diffusive motion within the nucleus rather than an ATP-
dependent motor protein [91].
CTCF has been demonstrated to regulate transcription of
several large DNA viruses including the γ-herpesviruses
Kaposi sarcoma-associated herpesvirus (KSHV) and
Epstein-Barr virus (EBV) [92–96]. Similarly, multiple CTCF
binding sites have been identified within the genomes of sev-
eral HPV types. These include a conserved cluster within the
late gene region found in over 80% of 125 types screened
(high- and low-risk) and also sites within the E2 ORF, present
in less than 20% of HPV types analysed and which appears to
be conserved in high-risk HPV types only [97, 98]. Using
HPV31 episome-containing cells as a model system, the
Laimins group showed that CTCF was predominantly recruit-
ed to the late gene region and that depletion of CTCF, or
mutation of the L2 binding site cluster resulted in reduced
episome copy number and failure of episomal establishment
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[97]. Somewhat in contrast to these findings, our laboratory
has shown that HPV18 genomes have enriched CTCF binding
at the high-risk HPV-specific E2 ORF with an absence of
binding in the late gene region, suggesting that different
high-risk HPV types have evolved different strategies of gene
expression control [52, 98]. Mutation of the single E2-CTCF
binding site in HPV18 had no effect on replication or mainte-
nance of HPV18 episomes, but resulted in increased early
transcript production and a concomitant increase in E6 and
E7 protein expression and cellular hyperproliferation [98].
Importantly, we showed that CTCF-mediated repression of
HPV early gene transcription via the stabilization of a chro-
matin loop formed between the E2 ORF and the URR. Rather
than being formed between two convergent CTCF binding
sites, as has been shown in the host genome, the CTCF-
dependent chromatin loop in HPV18 episomes is formed be-
tween CTCF bound at the E2 ORF and a second transcription
factor, Yin Yang 1 (YY1), bound at the viral URR [52] (Fig.
3a). CTCF and YY1 have been previously shown to directly
interact and co-operate in the stabilization of chromatin loops
between distant loci in the human genome, providing an alter-
native mechanism of chromatin organization [99, 100].
It is feasible that loop formation in the HPV genome occurs
via loop extrusion between the CTCF and YY1 anchor points
but whether this loop is stabilized by cohesin is currently
unknown although phosphorylated SMC1 (pSMC1), a struc-
tural component of cohesin rings, binds to HPV31 episomes
that appears to be important for viral genome amplification
[97]. Whether SMC1 also plays a role in HPV transcription
and/or whether cohesin is required for chromatin loop stabili-
zation has yet to be resolved. While YY1 is abundantly
expressed in undifferentiated keratinocytes and recruited to
the HPV URR, stimulation of keratinocyte differentiation
causes a dramatic reduction in YY1 protein expression and a
loss of YY1 recruitment to the URR (Fig. 3b). This causes a
loss of repressive chromatin loop formation in the viral ge-
nome, stimulating increased early gene transcription [52].
Whether the loss of chromatin loop formation in HPV18 ge-
nomes during keratinocyte differentiation is directly responsi-
ble for late promoter activation is presently unknown.
Interestingly, ChIP-Seq data available from the ENCODE
project [101] for HeLa cells have been analysed to define
histone and transcription factor occupancy on the integrated
HPV18 locus. While the CTCF binding site within the E2
ORF is maintained in the integrated HPV18 DNA, CTCF
protein was not detected at this site [102]. This may indicate
that the repression of viral transcription via CTCF-YY1 chro-
matin organization is abrogated in HPV-driven cancer cells, a
hypothesis we are currently testing. Since CTCF binding sites
have been shown to be a major hotspot for mutation in a
variety of cancers [103], the loss of CTCF binding to viral
DNA in tumours may represent a similar driving event in
cancer development.
Conclusions
Epigenetic regulation of HPV transcription is necessary for
episome establishment, genome maintenance and completion
of the productive HPV life cycle. The complex interplay of
positive and negative epigenetic regulation of HPV transcrip-
tion is inextricably linked to the differentiation status of the
infected cell; the viral genome exists in an epigenetically re-
pressed state in the undifferentiated basal cells with low-level
gene expression such that the episome can replicate but pre-
vent immune activation. As cells enter a programme of differ-
entiation, epigenetic repression of the viral genome is allevi-
ated and the viral chromatin structure is maintained in an
active state, resulting in increased expression of viral replica-
tion proteins and activation of the late promoter and capsid
protein production. This complex transcriptional programme,
requiring a plethora of host cell epigenetic regulators, appears
to be disrupted in HPV-induced carcinogenesis providing the
possibility of new therapeutic strategies against HPV-induced
disease.
Funding information The authors are funded by the Medical Research
Council (MRC; MR/N023498/1 and MR/R022011/1) and a Cancer
Research UK (CRUK) PhD studentship training award.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interest.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing, adap-
tation, distribution and reproduction in any medium or format, as long as
you give appropriate credit to the original author(s) and the source, pro-
vide a link to the Creative Commons licence, and indicate if changes were
made. The images or other third party material in this article are included
in the article's Creative Commons licence, unless indicated otherwise in a
credit line to the material. If material is not included in the article's
Creative Commons licence and your intended use is not permitted by
statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this
licence, visit http://creativecommons.org/licenses/by/4.0/.
References
1. Van Doorslaer K, Chen Z, Bernard HU, Chan PKS, DeSalle R,
Dillner J, Forslund O, Haga T, McBride AA, Villa LL, Burk RD,
Ictv Report C (2018) ICTV virus taxonomy profile:
Papillomaviridae. J Gen Virol 99(8):989–990. https://doi.org/10.
1099/jgv.0.001105
2. IARC WGotEoCRtH (2007) Human papillomaviruses. IARC
Monogr Eval Carcinog Risks Hum 90:1–636
3. Favre M, Breitburd F, Croissant O, Orth G (1977) Chromatin-like
structures obtained after alkaline disruption of bovine and human
papillomaviruses. J Virol 21(3):1205–1209
Semin Immunopathol
4. Straub E, Fertey J, Dreer M, Iftner T, Stubenrauch F (2015)
Characterization of the human papillomavirus 16 E8 promoter. J
Virol 89(14):7304–7313. https://doi.org/10.1128/JVI.00616-15
5. Graham SV (2017) Keratinocyte differentiation-dependent human
papillomavirus gene regulation. Viruses 9(9). https://doi.org/10.
3390/v9090245
6. Feeney KM, Parish JL (2009) Targeting mitotic chromosomes: a
conserved mechanism to ensure viral genome persistence. Proc
Biol Sci 276(1662):1535–1544. https://doi.org/10.1098/rspb.
2008.1642
7. Jang MK, Shen K, McBride AA (2014) Papillomavirus genomes
associate with BRD4 to replicate at fragile sites in the host ge-
nome. PLoS Pathog 10(5):e1004117. https://doi.org/10.1371/
journal.ppat.1004117
8. Androphy EJ, Lowy DR, Schiller JT (1987) Bovine papillomavi-
rus E2 trans-activating gene product binds to specific sites in pap-
illomavirus DNA. Nature 325(6099):70–73. https://doi.org/10.
1038/325070a0
9. Bernard BA, Bailly C, Lenoir MC, Darmon M, Thierry F, Yaniv
M (1989) The human papillomavirus type 18 (HPV18) E2 gene
product is a repressor of the HPV18 regulatory region in human
keratinocytes. J Virol 63(10):4317–4324
10. DongG, Broker TR, Chow LT (1994)Human papillomavirus type
11 E2 proteins repress the homologous E6 promoter by interfering
with the binding of host transcription factors to adjacent elements.
J Virol 68(2):1115–1127
11. Hou SY, Wu SY, Zhou T, Thomas MC, Chiang CM (2000)
Alleviation of human papillomavirus E2-mediated transcriptional
repression via formation of a TATA binding protein (or TFIID)-
TFIIB-RNA polymerase II-TFIIF preinitiation complex. Mol Cell
Biol 20(1):113–125
12. Stubenrauch F, Leigh IM, Pfister H (1996) E2 represses the late
gene promoter of human papillomavirus type 8 at high concentra-
tions by interfering with cellular factors. J Virol 70(1):119–126
13. Tan SH, Leong LE, Walker PA, Bernard HU (1994) The human
papillomavirus type 16 E2 transcription factor binds with low
cooperativity to two flanking sites and represses the E6 promoter
through displacement of Sp1 and TFIID. J Virol 68(10):6411–
6420
14. Schweiger MR, Ottinger M, You J, Howley PM (2007) Brd4-
independent transcriptional repression function of the papilloma-
virus e2 proteins. J Virol 81(18):9612–9622. https://doi.org/10.
1128/JVI.00447-07
15. Smith JA, White EA, Sowa ME, Powell ML, Ottinger M, Harper
JW, Howley PM (2010) Genome-wide siRNA screen identifies
SMCX, EP400, and Brd4 as E2-dependent regulators of human
papillomavirus oncogene expression. Proc Natl Acad Sci U S A
107(8):3752–3757. https://doi.org/10.1073/pnas.0914818107
16. Wu SY, Lee AY, Hou SY, Kemper JK, Erdjument-Bromage H,
Tempst P, Chiang CM (2006) Brd4 links chromatin targeting to
HPV transcriptional silencing. Genes Dev 20(17):2383–2396.
https://doi.org/10.1101/gad.1448206
17. Wang X, Meyers C, Wang HK, Chow LT, Zheng ZM (2011)
Construction of a full transcription map of human papillomavirus
type 18 during productive viral infection. J Virol 85(16):8080–
8092. https://doi.org/10.1128/JVI.00670-11
18. Kurg R, Uusen P, Vosa L, Ustav M (2010) Human papillomavirus
E2 protein with single activation domain initiates HPV18 genome
replication, but is not sufficient for long-termmaintenance of virus
genome. Virology 408(2):159–166. https://doi.org/10.1016/j.
virol.2010.09.010
19. Moody CA, Laimins LA (2010) Human papillomavirus
oncoproteins: pathways to transformation. Nat Rev Cancer
10(8):550–560. https://doi.org/10.1038/nrc2886
20. Soto D, Song C, McLaughlin-Drubin ME (2017) Epigenetic alter-
ations in human papillomavirus-associated cancers. Viruses 9(9).
https://doi.org/10.3390/v9090248
21. Moody CA, Laimins LA (2009) Human papillomaviruses activate
the ATM DNA damage pathway for viral genome amplification
upon differentiation. PLoS Pathog 5(10):e1000605. https://doi.
org/10.1371/journal.ppat.1000605
22. Egawa N, Wang Q, Griffin HM, Murakami I, Jackson D,
Mahmood R, Doorbar J (2017) HPV16 and 18 genome amplifi-
cation show different E4-dependence, with 16E4 enhancing E1
nuclear accumulation and replicative efficiency via its cell cycle
arrest and kinase activation functions. PLoS Pathog 13(3):
e1006282. https://doi.org/10.1371/journal.ppat.1006282
23. Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ
(1997) Crystal structure of the nucleosome core particle at 2.8 A
resolution. Nature 389(6648):251–260. https://doi.org/10.1038/
38444
24. Biswas S, Rao CM (2018) Epigenetic tools (the writers, the
readers and the erasers) and their implications in cancer therapy.
Eur J Pharmacol 837:8–24. https://doi.org/10.1016/j.ejphar.2018.
08.021
25. Cavalli G, Heard E (2019) Advances in epigenetics link genetics
to the environment and disease. Nature 571(7766):489–499.
https://doi.org/10.1038/s41586-019-1411-0
26. Waddington CH (1942) Canalization of development and the in-
heritance of acquired characters. Nature 150:563–565. https://doi.
org/10.1038/1831654a0
27. Moore LD, Le T, Fan G (2013) DNA methylation and its basic
function. Neuropsychopharmacology 38(1):23–38. https://doi.
org/10.1038/npp.2012.112
28. Bird A, Taggart M, Frommer M, Miller OJ, Macleod D (1985) A
fraction of the mouse genome that is derived from islands of
nonmethylated, CpG-rich DNA. Cell 40(1):91–99. https://doi.
org/10.1016/0092-8674(85)90312-5
29. Jones PA (2012) Functions of DNA methylation: islands, start
sites, gene bodies and beyond. Nat Rev Genet 13(7):484–492.
https://doi.org/10.1038/nrg3230
30. Keshet I, Lieman-Hurwitz J, Cedar H (1986) DNA methylation
affects the formation of active chromatin. Cell 44(4):535–543.
https://doi.org/10.1016/0092-8674(86)90263-1
31. Boyes J, Bird A (1991) DNA methylation inhibits transcription
indirectly via a methyl-CpG binding protein. Cell 64(6):1123–
1134. https://doi.org/10.1016/0092-8674(91)90267-3
32. Stunkel W, Bernard HU (1999) The chromatin structure of the
long control region of human papillomavirus type 16 represses
viral oncoprotein expression. J Virol 73(3):1918–1930
33. Swindle CS, Engler JA (1998) Association of the human papillo-
mavirus type 11 E1 protein with histone H1. J Virol 72(3):1994–
2001
34. Lefebvre O, Steger G, YanivM (1997) Synergistic transcriptional-
activation by the papillomavirus E2 protein occurs after DNA
binding and correlates with a change in chromatin structure. J
Mol Biol 266(3):465–478. https://doi.org/10.1006/jmbi.1996.
0807
35. del Mar Pena LM, Laimins LA (2001) Differentiation-dependent
chromatin rearrangement coincides with activation of human pap-
illomavirus type 31 late gene expression. J Virol 75(20):10005–
10013. https://doi.org/10.1128/JVI.75.20.10005-10013.2001
36. Bannister AJ, Kouzarides T (1996) The CBP co-activator is a
histone acetyltransferase. Nature 384(6610):641–643. https://doi.
org/10.1038/384641a0
37. Imhof A, Yang XJ, Ogryzko VV, Nakatani Y, Wolffe AP, Ge H
(1997) Acetylation of general transcription factors by histone ace-
tyltransferases. Curr Biol 7(9):689–692. https://doi.org/10.1016/
s0960-9822(06)00296-x
Semin Immunopathol
38. Lee D, Lee B, Kim J, Kim DW, Choe J (2000) cAMP response
element-binding protein-binding protein binds to human papillo-
mavirus E2 protein and activates E2-dependent transcription. J
Biol Chem 275(10):7045–7051
39. Patel D, Huang SM, Baglia LA, McCance DJ (1999) The E6
protein of human papillomavirus type 16 binds to and inhibits
co-activation by CBP and p300. EMBO J 18(18):5061–5072.
https://doi.org/10.1093/emboj/18.18.5061
40. Zimmermann H, Degenkolbe R, Bernard HU, O’Connor MJ
(1999) The human papillomavirus type 16 E6 oncoprotein can
down-regulate p53 activity by targeting the transcriptional coacti-
vator CBP/p300. J Virol 73(8):6209–6219
41. Bernat A, Avvakumov N,Mymryk JS, Banks L (2003) Interaction
between the HPV E7 oncoprotein and the transcriptional coacti-
vator p300. Oncogene 22(39):7871–7881. https://doi.org/10.
1038/sj.onc.1206896
42. Kruppel U, Muller-Schiffmann A, Baldus SE, Smola-Hess S,
Steger G (2008) E2 and the co-activator p300 can cooperate in
activation of the human papillomavirus type 16 early promoter.
Virology 377(1):151–159. https://doi.org/10.1016/j.virol.2008.
04.006
43. Bouallaga I, Teissier S, YanivM, Thierry F (2003) HMG-I(Y) and
the CBP/p300 coactivator are essential for human papillomavirus
type 18 enhanceosome transcriptional activity. Mol Cell Biol
23(7):2329–2340. https://doi.org/10.1128/mcb.23.7.2329-2340.
2003
44. Valencia-Hernandez A, Cuevas-Bennett C, Garrido E (2007)
Transcriptional regulation of human papillomavirus type 18
P105 promoter by the co-activator CBP. Intervirology 50(6):
418–425. https://doi.org/10.1159/000112917
45. He H, Luo Y (2012) Brg1 regulates the transcription of human
papillomavirus type 18 E6 and E7 genes. Cell Cycle 11(3):617–
627. https://doi.org/10.4161/cc.11.3.19115
46. He H, Lai Y, Hao Y, Liu Y, Zhang Z, Liu X, Guo C, Zhang M,
Zhou H, Wang N, Luo XG, Huo L, Ma W, Zhang TC (2017)
Selective p300 inhibitor C646 inhibited HPVE6-E7 genes, altered
glucosemetabolism and induced apoptosis in cervical cancer cells.
Eur J Pharmacol 812:206–215. https://doi.org/10.1016/j.ejphar.
2017.06.005
47. Jha S, Vande Pol S, Banerjee NS, Dutta AB, Chow LT, Dutta A
(2010) Destabilization of TIP60 by human papillomavirus E6 re-
sults in attenuation of TIP60-dependent transcriptional regulation
and apoptotic pathway. Mol Cell 38(5):700–711. https://doi.org/
10.1016/j.molcel.2010.05.020
48. Langsfeld ES, Bodily JM, Laimins LA (2015) The deacetylase
sirtuin 1 regulates human papillomavirus replication by modulat-
ing histone acetylation and recruitment of DNA damage factors
NBS1 and Rad51 to viral genomes. PLoS Pathog 11(9):e1005181.
https://doi.org/10.1371/journal.ppat.1005181
49. Das D, Smith N, Wang X, Morgan IM (2017) The deacetylase
SIRT1 regulates the replication properties of human papillomavi-
rus 16 E1 and E2. J Virol 91(10). https://doi.org/10.1128/JVI.
00102-17
50. Das D, Bristol ML, Smith NW, James CD, Wang X, Pichierri P,
Morgan IM (2019) Werner helicase control of human papilloma-
virus 16 E1-E2 DNA replication is regulated by SIRT1
deacetylation. Mbio 10(4):e00263–e00219. https://doi.org/10.
1128/mBio.01635-19
51. Dreer M, Fertey J, van de Poel S, Straub E, Madlung J, Macek B,
Iftner T, Stubenrauch F (2016) Interaction of NCOR/SMRT re-
pressor complexes with papillomavirus E8^E2C proteins inhibits
viral replication. PLoS Pathog 12(4):e1005556. https://doi.org/10.
1371/journal.ppat.1005556
52. Pentland I, Campos-Leon K, Cotic M, Davies KJ, Wood CD,
Groves IJ, Burley M, Coleman N, Stockton JD, Noyvert B,
Beggs AD, West MJ, Roberts S, Parish JL (2018) Disruption of
CTCF-YY1-dependent looping of the human papillomavirus ge-
nome activates differentiation-induced viral oncogene transcrip-
tion. PLoS Biol 16(10):e2005752. https://doi.org/10.1371/
journal.pbio.2005752
53. Groves IJ, Knight EL, Ang QY, Scarpini CG, Coleman N (2016)
HPV16 oncogene expression levels during early cervical carcino-
genesis are determined by the balance of epigenetic chromatin
modifications at the integrated virus genome. Oncogene 35(36):
4773–4786. https://doi.org/10.1038/onc.2016.8
54. Gautam D, Johnson BA, Mac M, Moody CA (2018) SETD2-
dependent H3K36me3 plays a critical role in epigenetic regulation
of the HPV31 life cycle. PLoS Pathog 14(10):e1007367. https://
doi.org/10.1371/journal.ppat.1007367
55. Soto DR, Barton C, Munger K, McLaughlin-Drubin ME (2017)
KDM6A addiction of cervical carcinoma cell lines is triggered by
E7 and mediated by p21(CIP1) suppression of replication stress.
Plos Pathogens 13(10):e1006661. https://doi.org/10.1371/journal.
ppat.1006661
56. Danos O, Katinka M, Yaniv M (1980) Molecular cloning, refined
physical map and heterogeneity of methylation sites of papilloma
virus type 1a DNA. Eur J Biochem 109(2):457–461. https://doi.
org/10.1111/j.1432-1033.1980.tb04815.x
57. Burnett TS, Sleeman JP (1984) Uneven distribution of methyla-
tion sites within the human papillomavirus la genome: possible
relevance to viral gene expression. Nucleic Acids Res 12(23):
8847–8860. https://doi.org/10.1093/nar/12.23.8847
58. Rosl F, Durst M, Zur Hausen H (1988) Selective suppression of
human papillomavirus transcription in non-tumorigenic cells by 5-
azacytidine. EMBO J 7(5):1321–1328
59. Rosl F, Arab A, Klevenz B, zur Hausen H (1993) The effect of
DNA methylation on gene regulation of human papillomaviruses.
J GenVirol 74(Pt 5):791–801. https://doi.org/10.1099/0022-1317-
74-5-791
60. Thain A,Webster K, Emery D, Clarke AR, Gaston K (1997) DNA
binding and bending by the human papillomavirus type 16 E2
protein - recognition of an extended binding site. J Biol Chem
272(13):8236–8242. https://doi.org/10.1074/jbc.272.13.8236
61. Stanley MA, Browne HM, Appleby M, Minson AC (1989)
Properties of a non-tumorigenic human cervical keratinocyte cell
line. Int J Cancer 43(4):672–676
62. Kim K, Garner-Hamrick PA, Fisher C, Lee D, Lambert PF (2003)
Methylation patterns of papillomavirus DNA, its influence on E2
function, and implications in viral infection. J Virol 77(23):
12450–12459. https://doi.org/10.1128/jvi.77.23.12450-12459.
2003
63. Leonard SM, Pereira M, Roberts S, Cuschieri K, Nuovo G,
Athavale R, Young L, Ganesan R, Woodman CB (2016)
Evidence of disrupted high-risk human papillomavirus DNA in
morphologically normal cervices of older women. Sci Rep 6:
20847. https://doi.org/10.1038/srep20847
64. Kalantari M, Calleja-Macias IE, Tewari D, Hagmar B, Lie K,
Barrera-Saldana HA, Wiley DJ, Bernard HU (2004) Conserved
methylation patterns of human papillomavirus type 16 DNA in
asymptomatic infection and cervical neoplasia. J Virol 78(23):
12762–12772. https://doi.org/10.1128/JVI.78.23.12762-12772.
2004
65. Mirabello L, SchiffmanM, Ghosh A, Rodriguez AC, Vasiljevic N,
Wentzensen N, Herrero R, Hildesheim A, Wacholder S, Scibior-
Bentkowska D, Burk RD, Lorincz AT (2013) Elevated methyla-
tion of HPV16 DNA is associated with the development of high
grade cervical intraepithelial neoplasia. Int J Cancer 132(6):1412–
1422. https://doi.org/10.1002/ijc.27750
66. Mirabello L, Sun C, Ghosh A, Rodriguez AC, Schiffman M,
Wentzensen N, Hildesheim A, Herrero R, Wacholder S, Lorincz
A, Burk RD (2012)Methylation of human papillomavirus type 16
genome and risk of cervical precancer in a Costa Rican
Semin Immunopathol
population. J Natl Cancer Inst 104(7):556–565. https://doi.org/10.
1093/jnci/djs135
67. Sun C, Reimers LL, Burk RD (2011) Methylation of HPV16
genome CpG sites is associated with cervix precancer and cancer.
Gynecol Oncol 121(1):59–63. https://doi.org/10.1016/j.ygyno.
2011.01.013
68. Reuschenbach M, Huebbers CU, Prigge ES, Bermejo JL, Kalteis
MS, Preuss SF, Seuthe IM, Kolligs J, Speel EJ, Olthof N, Kremer
B, Wagner S, Klussmann JP, Vinokurova S, von Knebel DM
(2015) Methylation status of HPV16 E2-binding sites classifies
subtypes of HPV-associated oropharyngeal cancers. Cancer
121(12):1966–1976. https://doi.org/10.1002/cncr.29315
69. Anayannis NV, Schlecht NF, Ben-DayanM, Smith RV, Belbin TJ,
Ow TJ, Blakaj DM, Burk RD, Leonard SM,Woodman CB, Parish
JL, Prystowsky MB (2018) Association of an intact E2 gene with
higher HPV viral load, higher viral oncogene expression, and
improved clinical outcome in HPV16 positive head and neck
squamous cell carcinoma. PLoS One 13(2):e0191581. https://
doi.org/10.1371/journal.pone.0191581
70. Ozbun MA, Meyers C (1997) Characterization of late gene tran-
scripts expressed during vegetative replication of human papillo-
mavirus type 31b. J Virol 71(7):5161–5172
71. Ozbun MA, Meyers C (1998) Temporal usage of multiple pro-
moters during the life cycle of human papillomavirus type 31b. J
Virol 72(4):2715–2722
72. Bodily JM, Meyers C (2005) Genetic analysis of the human pap-
illomavirus type 31 differentiation-dependent late promoter. J
Virol 79(6):3309–3321. https://doi.org/10.1128/JVI.79.6.3309-
3321.2005
73. Wooldridge TR, Laimins LA (2008) Regulation of human papil-
lomavirus type 31 gene expression during the differentiation-
dependent life cycle through histone modifications and transcrip-
tion factor binding. Virology 374(2):371–380. https://doi.org/10.
1016/j.virol.2007.12.011
74. O’Connor MJ, Tan SH, Tan CH, Bernard HU (1996) YY1 re-
presses human papillomavirus type 16 transcription by quenching
AP-1 activity. J Virol 70(10):6529–6539
75. Bauknecht T, Angel P, Royer HD, zur Hausen H (1992)
Identification of a negative regulatory domain in the human pap-
illomavirus type 18 promoter: interaction with the transcriptional
repressor YY1. EMBO J 11(12):4607–4617
76. Srinivasan L, Atchison ML (2004) YY1 DNA binding and PcG
recruitment requires CtBP. Genes Dev 18(21):2596–2601. https://
doi.org/10.1101/gad.1228204
77. Wilkinson F, Pratt H, AtchisonML (2010) PcG recruitment by the
YY1 REPO domain can be mediated by Yaf2. J Cell Biochem
109(3):478–486. https://doi.org/10.1002/jcb.22424
78. Wilkinson FH, Park K, Atchison ML (2006) Polycomb recruit-
ment to DNA in vivo by the YY1 REPO domain. Proc Natl Acad
Sci U S A 103(51):19296–19301. https://doi.org/10.1073/pnas.
0603564103
79. Wang H, Wang L, Erdjument-Bromage H, Vidal M, Tempst P,
Jones RS, Zhang Y (2004) Role of histone H2A ubiquitination
in Polycomb silencing. Nature 431(7010):873–878. https://doi.
org/10.1038/nature02985
80. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst
P, Jones RS, Zhang Y (2002) Role of histone H3 lysine 27 meth-
ylation in Polycomb-group silencing. Science 298(5595):1039–
1043. https://doi.org/10.1126/science.1076997
81. Holland D, Hoppe-Seyler K, Schuller B, Lohrey C, Maroldt J,
Durst M, Hoppe-Seyler F (2008) Activation of the enhancer of
zeste homologue 2 gene by the human papillomavirus E7
oncoprotein. Cancer Res 68(23):9964–9972. https://doi.org/10.
1158/0008-5472.CAN-08-1134
82. Hyland PL, McDade SS, McCloskey R, Dickson GJ, Arthur K,
McCance DJ, Patel D (2011) Evidence for alteration of EZH2,
BMI1, and KDM6A and epigenetic reprogramming in human
papillomavirus type 16 E6/E7-expressing keratinocytes. J Virol
85(21):10999–11006. https://doi.org/10.1128/JVI.00160-11
83. Saidj D, Cros MP, Hernandez-Vargas H, Guarino F, Sylla BS,
Tommasino M, Accardi R (2013) Oncoprotein E7 from beta hu-
man papillomavirus 38 induces formation of an inhibitory com-
plex for a subset of p53-regulated promoters. J Virol 87(22):
12139–12150. https://doi.org/10.1128/JVI.01047-13
84. Cha TL, Zhou BHP, Xia WY, Wu YD, Yang CC, Chen CT, Ping
B, Otte AP, Hung MC (2005) Akt-mediated phosphorylationof
EZH2 suppresses methylation of lysine 27 in histone H3.
Science 310(5746):306–310. https://doi.org/10.1126/science.
1118947
85. Kim TH, Abdullaev ZK, Smith AD, Ching KA, Loukinov DI,
Green RD, Zhang MQ, Lobanenkov VV, Ren B (2007) Analysis
of the vertebrate insulator protein CTCF-binding sites in the hu-
man genome. Cell 128(6):1231–1245. https://doi.org/10.1016/j.
cell.2006.12.048
86. Braccioli L, de Wit E (2019) CTCF: a Swiss-army knife for ge-
nome organization and transcription regulation. Essays Biochem
63(1):157–165. https://doi.org/10.1042/EBC20180069
87. Wendt KS, Yoshida K, Itoh T, Bando M, Koch B, Schirghuber E,
Tsutsumi S, Nagae G, Ishihara K, Mishiro T, Yahata K, Imamoto
F, Aburatani H, NakaoM, Imamoto N, Maeshima K, Shirahige K,
Peters JM (2008) Cohesin mediates transcriptional insulation by
CCCTC-binding factor. Nature 451(7180):796–801. https://doi.
org/10.1038/nature06634
88. Splinter E, Heath H, Kooren J, Palstra RJ, Klous P, Grosveld F,
Galjart N, de Laat W (2006) CTCF mediates long-range chroma-
tin looping and local histone modification in the beta-globin locus.
Genes Dev 20(17):2349–2354. https://doi.org/10.1101/gad.
399506
89. Rao SS, Huntley MH, Durand NC, Stamenova EK, Bochkov ID,
Robinson JT, Sanborn AL, Machol I, Omer AD, Lander ES,
Aiden EL (2014) A 3D map of the human genome at kilobase
resolution reveals principles of chromatin looping. Cell 159(7):
1665–1680. https://doi.org/10.1016/j.cell.2014.11.021
90. deWit E, Vos ES, Holwerda SJ, Valdes-Quezada C, VerstegenMJ,
Teunissen H, Splinter E, Wijchers PJ, Krijger PH, de Laat W
(2015) CTCF binding polarity determines chromatin looping.
Mol Cell 60(4):676–684. https://doi.org/10.1016/j.molcel.2015.
09.023
91. Brackley CA, Johnson J, Michieletto D, Morozov AN, Nicodemi
M, Cook PR, Marenduzzo D (2018) Extrusion without a motor: a
new take on the loop extrusion model of genome organization.
Nucleus 9(1):95–103. https://doi.org/10.1080/19491034.2017.
1421825
92. Pentland I, Parish JL (2015) Targeting CTCF to control virus gene
expression: a common theme amongst diverse DNA viruses.
Viruses 7(7):3574–3585. https://doi.org/10.3390/v7072791
93. Kang H,Wiedmer A, Yuan Y, Robertson E, Lieberman PM (2011)
Coordination of KSHV latent and lytic gene control by CTCF-
cohesin mediated chromosome conformation. PLoS Pathog 7(8):
e1002140. https://doi.org/10.1371/journal.ppat.1002140
94. Tempera I, Lieberman PM (2010) Chromatin organization of
gammaherpesvirus latent genomes. Biochim Biophys Acta
1799(3–4):236–245. https://doi.org/10.1016/j.bbagrm.2009.10.
004
95. Chau CM, Zhang XY, McMahon SB, Lieberman PM (2006)
Regulation of Epstein-Barr virus latency type by the chromatin
boundary factor CTCF. J Virol 80(12):5723–5732. https://doi.org/
10.1128/JVI.00025-06
96. Chen HS, Martin KA, Lu F, Lupey LN, Mueller JM, Lieberman
PM, Tempera I (2014) Epigenetic deregulation of the
LMP1/LMP2 locus of Epstein-Barr virus by mutation of a single
Semin Immunopathol
CTCF-cohesin binding site. J Virol 88(3):1703–1713. https://doi.
org/10.1128/JVI.02209-13
97. Mehta K, GunasekharanV, SatsukaA, Laimins LA (2015)Human
papillomaviruses activate and recruit SMC1 cohesin proteins for
the differentiation-dependent life cycle through association with
CTCF insulators. PLoS Pathog 11(4):e1004763. https://doi.org/
10.1371/journal.ppat.1004763
98. Paris C, Pentland I, Groves I, Roberts DC, Powis SJ, Coleman N,
Roberts S, Parish JL (2015) CCCTC-binding factor recruitment to
the early region of the human papillomavirus 18 genome regulates
viral oncogene expression. J Virol 89(9):4770–4785. https://doi.
org/10.1128/JVI.00097-15
99. Beagan JA, Duong MT, Titus KR, Zhou L, Cao Z, Ma J,
Lachanski CV, Gillis DR, Phillips-Cremins JE (2017) YY1 and
CTCF orchestrate a 3D chromatin looping switch during early
neural lineage commitment. Genome Res. https://doi.org/10.
1101/gr.215160.116
100. Donohoe ME, Zhang LF, Xu N, Shi Y, Lee JT (2007)
Identification of a Ctcf cofactor, Yy1, for the X chromosome
binary switch. Mol Cell 25(1):43–56. https://doi.org/10.1016/j.
molcel.2006.11.017
101. Rosenbloom KR, Dreszer TR, Long JC, Malladi VS, Sloan
CA, Raney BJ, Cline MS, Karolchik D, Barber GP,
Clawson H, Diekhans M, Fujita PA, Goldman M, Gravell
RC, Harte RA, Hinrichs AS, Kirkup VM, Kuhn RM,
Learned K, Maddren M, Meyer LR, Pohl A, Rhead B,
Wong MC, Zweig AS, Haussler D, Kent WJ (2012)
ENCODE whole-genome data in the UCSC genome brows-
er: update 2012. Nucleic Acids Res 40(Database issue):
D912–D917. https://doi.org/10.1093/nar/gkr1012
102. Johannsen E, Lambert PF (2013) Epigenetics of human papillo-
maviruses. Virology 445(1–2):205–212. https://doi.org/10.1016/j.
virol.2013.07.016
103. Katainen R, Dave K, Pitkanen E, Palin K, Kivioja T, Valimaki N,
Gylfe AE, Ristolainen H, Hanninen UA, Cajuso T, Kondelin J,
Tanskanen T, Mecklin JP, Jarvinen H, Renkonen-Sinisalo L,
Lepisto A, Kaasinen E, Kilpivaara O, Tuupanen S, Enge M,
Taipale J, Aaltonen LA (2015) CTCF/cohesin-binding sites are
frequently mutated in cancer. Nat Genet 47(7):818–821. https://
doi.org/10.1038/ng.3335
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
Semin Immunopathol
